Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Admilparant and Nintedanib PK Interaction, Bioavailability, and Food Effect Study
NCT06568458Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of admilparant in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Serum Concentration, Area under the plasma concentration-time curve within a dosing interval and 2 more. Started Sep 2024; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06568458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568458.